Portfolio Inertia Is Catching Up With These Funds

The case for patience weakens when new ideas rarely challenge these funds’ old convictions.

Securities in This Article
FactSet Research Systems Inc
(FDS)
Guidewire Software Inc
(GWRE)
Danaher Corp
(DHR)
Calvert Equity Fund Class A
(CSIEX)
Baron Generational Growth Fund Retail Shares
(BGRFX)

Patience is a virtue for long-term investors. However, patience becomes harder to distinguish from inertia when a team’s research process offers little evidence that compelling new ideas are waiting in the wings.

That question hangs over Calvert Equity CSIEX and Baron Generational Growth BGRFX. We downgraded both funds’ Process ratings to Average from Above Average. Neither suffers from a broken investment philosophy. Rather, each has stopped demonstrating enough of an advantage in generating and acting on investment ideas to warrant an Above Average rating.

Calvert Equity Stands Still

Calvert Equity’s managers favor profitable, financially sound companies that are capable of compounding value for years. The resulting portfolio has low turnover and plenty of familiar names.

Perhaps too familiar. Today’s portfolio looks much like it did five years ago. Few new holdings have proved compelling enough to push aside longtime positions like Thermo Fisher Scientific TMO and Danaher DHR. Meanwhile, some former growth stalwarts have matured, helping pull the portfolio from large growth toward large blend.

Other constraints make renewal harder. The managers avoid businesses that fail to meet their quality standards and cap individual positions at 5%. They have also stayed away from semiconductors, which represented 16% of the Morningstar US Large Cap Index (the large-blend Morningstar Category’s benchmark) in October 2026. These choices reflect a coherent risk-conscious philosophy, but they leave less room to compensate for old ideas that have lost their edge.

Baron Holds Tighter

Ron Baron has made patience a defining feature of Baron Generational Growth since its 1994 launch. His willingness to hold exceptional businesses for years helped build an enviable long-term record—and substantial unrealized capital gains.

Persistent outflows have made the portfolio’s large embedded gains increasingly consequential. Baron has generally met redemptions by selling smaller holdings where conviction or embedded gains are lower. That narrowed the portfolio to just 18 stocks in September 2026, down from about 60 a decade earlier, with nearly 90% of assets in its top 10 positions.

That concentration raises the stakes around the manager’s existing convictions. Software and data businesses, including FactSet FDS and Guidewire GWRE, accounted for over one-third of assets, and many of these have fallen sharply as investors questioned how artificial intelligence might disrupt their businesses. Baron remains confident in their long-term prospects, but the portfolio now has less room for error if those judgments prove wrong.

Concentration by itself is not the problem. Baron has long succeeded by holding his best ideas for years, and the firm now has a much deeper research bench than it did earlier in his tenure. The bigger concern is that the portfolio offers little evidence that this expanded research effort is producing enough compelling alternatives to challenge the incumbents. That weakens the case that the process still possesses the advantages needed to merit an Above Average rating.

Conviction Needs Competition

The funds’ experienced investors and coherent philosophies still deserve respect. Long-term investing can thrive when new research continually tests old conclusions and a strong pipeline of ideas forces existing holdings to earn their place.

Calvert Equity and Baron Generational Growth currently provide less evidence of that competitive tension. Patient investors do not need to trade often, but they do need to keep earning the decision not to.

This article first appeared in the October 2026 issue of Morningstar FundInvestor. Download a complimentary copy of FundInvestor by visiting this website.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

Sponsor Center